Kinaxo
Biotechnologies will apply its phosphoproteomics technology
PhosphoScout® to support targeted treatment approaches currently under development at
Roche Diagnostics. PhosphoScout enables the identification of regulated protein phosphorylation sites in response to therapeutic antibody or kinase-inhibitor treatment, according to Kinaxo.
Using quantitative mass spectrometry, up to 15,000 phosphorylation sites can be monitored in a single experiment, the company claims. This facilitates analysis of the phosphoproteome in patient samples, animal models, and cell culture on a global scale.